EQUIPE ELECTRONICS LIMITED

Financial Health Score: B- (Stable but Diminishing)

Explanation: The company is in a state of "chronic atrophy." While it possesses a robust immune system against short-term insolvency (excellent liquidity), the business has experienced a severe reduction in its overall mass over the last few years. The patient is surviving, but it is a fraction of its former size, with no active workforce and steadily declining equity.

Key Vital Signs

1. Liquidity (Current Ratio): 6.32:1 (Healthy) * Measurement: Current Assets (£125,205) / Current Liabilities (£19,814) * Interpretation: The company has more than six times the current assets needed to cover its immediate debts. This is a very healthy cash position, meaning there is no risk of short-term cardiac arrest (insolvency). However, an overly high current ratio can sometimes indicate that assets are sitting idle rather than being reinvested into growth.

2. Net Asset Trajectory (Declining / Atrophying) * Measurement: Net Assets dropped from £650,886 (2022) to £105,484 (2025). * Interpretation: The company's overall net worth has steadily decreased over the last three years. This represents significant weight loss—while the patient is not bleeding out rapidly, they are slowly losing vitality year over year.

3. Leverage (Debt-to-Equity): 0.19:1 (Low Risk) * Measurement: Total Liabilities (£19,814) / Shareholders' Funds (£105,484) * Interpretation: The business has very little reliance on external debt. It is operating largely on its own retained resources, which means creditors hold very little power over the company's future.

4. Pulse (Employees): 0 (Flatline) * Measurement: Average number of employees during 2024 and 2025 was Nil. * Interpretation: A company with zero employees is either a shell, a purely passive asset-holding vehicle, or an owner-operated lifestyle business where the directors take drawings instead of payroll. The business is not respirating in the traditional sense of a trading enterprise.

Diagnosis

Chronic Atrophy following Acute Fluctuations

Looking at the medical history, Equipe Electronics Limited experienced dramatic physiological changes between 2019 and 2022, with total assets spiking to nearly £1.7 million in 2020 and £975,000 in 2022. Since that peak, the business has drastically downsized. Total assets have fallen to £125,298 as of May 2025.

The current diagnosis is a business that has transitioned from an active, potentially large-scale operation into a micro-entity with no staff and minimal liabilities. The presence of "Advances, credit and guarantees granted to directors" in the accounts, combined with the steady decline in net assets, strongly suggests that the directors (who are also the 75%+ shareholders) are extracting value from the business—either via dividends, directors' loans, or repayments of credit.

This is not necessarily a symptom of distress; for a 30-year-old private company, this often represents a "harvesting" phase where the owners are drawing down the company's accumulated wealth. However, the lack of reinvestment into fixed assets (which sit at a mere £93) and the lack of employees indicate that the business is not actively pursuing growth or research and development, despite its SIC code classifying it as a research and experimental development firm.

Prognosis

Stable but Terminal (as a growing enterprise)

The immediate future is secure. With minimal liabilities and a strong cash position, the company is in no danger of collapsing. However, unless the directors choose to reinject capital and energy into the business, it will continue to slowly diminish as assets are extracted or depleted. The company appears to be in a managed wind-down or passive holding state rather than an active trading phase.

Recommendations

1. Clarify the Strategic Intent: Determine if the current "micro" state is intentional. If the visual simulation business is no longer the primary focus, the directors should decide whether to formally dormant the company or continue using it as a low-overhead vehicle.
2. Monitor Directors' Accounts: Keep a close eye on the directors' loan accounts and advances. While currently manageable, over-extraction can quickly turn a healthy balance sheet anemic if liabilities begin to outpace asset realizations.
3. Asset Reassessment: With fixed assets at just £93, the company clearly isn't investing in equipment or IP. If the intent is to revive the "research and experimental development" aspect of the business, a capital transfusion (reinvestment) will be necessary to stimulate new growth.